Genmab makes $8bn acquisition to boost late-stage antibody therapy pipeline
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
List view / Grid view
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
The acquisition will give Genmab worldwide rights to three clinical candidates including a potential best-in-class folate receptor alpha (FRα)-targeted ADC for ovarian cancer.